Search results for "Colon Cancer"

showing 10 items of 157 documents

Deciphering human γδ T cell response in cancer: Lessons from tumor‐infiltrating γδ T cells

2020

The finding that γδ T cells are present among tumor-infiltrating lymphocytes in humans suggests they participate in tumor immune surveillance, but their relevance is unclear because the relative abundance of tumor-infiltrating γδ T cells correlates with positive or negative, or even do not correlate with prognosis. This likely depends on the fact that tumor-infiltrating γδ T cells may play substantially different effector or regulatory functions, and correlation with patient's prognosis relies on distinct γδ T cell subsets in the context of the tumor. There is interest to exploit γδ T cells in tumor immunotherapy, but to make this approach successful there is urgent need to fully understand…

0301 basic medicine[SDV]Life Sciences [q-bio]medicine.medical_treatmentT cellImmunologyContext (language use)BiologyTumor-infiltrating lymphocytesclinical correlationcolon cancer tumor microenvironment tumor-infiltrating lymphocytes γδ T lymphocytesClinical correlazion03 medical and health sciencesLymphocytes Tumor-Infiltrating0302 clinical medicineT-Lymphocyte SubsetsNeoplasmsmedicineHumansImmunology and AllergyComputingMilieux_MISCELLANEOUSTumor microenvironmentTumor-infiltrating lymphocytesEffectorCancerReceptors Antigen T-Cell gamma-deltaImmunotherapyGamma-delta T lymphocytesmedicine.diseaseColon cancer3. Good health030104 developmental biologymedicine.anatomical_structureTumor microenvironmentCancer researchEx vivo030215 immunologyImmunological Reviews
researchProduct

Distinctive features of tumor-infiltrating γδ T lymphocytes in human colorectal cancer.

2017

γδ T cells usually infiltrate many different types of cancer, but it is unclear whether they inhibit or promote tumor progression. Moreover, properties of tumor-infiltrating γδ T cells and those in the corresponding normal tissue remain largely unknown. Here we have studied features of γδ T cells in colorectal cancer, normal colon tissue and peripheral blood, and correlated their levels with clinicopathologic hallmarks. Flow cytometry and transcriptome analyses showed that the tumor comprised a highly variable rate of TILs (5–90%) and 4% γδ T cells on average, with the majority expressing Vδ1. Most Vδ1 and Vδ2 T cells showed a predominant effector memory phenotype and had reduced production…

0301 basic medicinelcsh:Immunologic diseases. Allergycolon cancer; DFS; IFN-g; TILs; gd T cells; Immunology and Allergy; Immunology; OncologyColorectal cancerImmunologyBiologyifn-γDFStilslcsh:RC254-28203 medical and health sciencesIFN-gmedicineCytotoxic T cellImmunology and AllergyOriginal ResearchSettore MED/04 - Patologia Generaleγδ t cellsCancergd T cellTILmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologycolon cancerOncologyTumor progressionImmunologylcsh:RC581-607Oncoimmunology
researchProduct

The Anti-Cancer Effect of Mangifera indica L. Peel Extract is Associated to γH2AX-mediated Apoptosis in Colon Cancer Cells

2019

Ethanolic extracts from Mangifera indica L. have been proved to possess anti-tumor properties in many cancer systems. However, although most effects have been demonstrated with fruit pulp extract, the underlying molecular mechanisms of mango peel are still unclear. This study was designed to explore the effects of mango peel extract (MPE) on colon cancer cell lines. MPE affected cell viability and inhibited the colony formation trend of tumor cells, while no effects were observed in human dermal fibroblasts used as a non-cancerous cell line model. These events were a consequence of the induction of apoptosis associated to reactive oxygen species (ROS) production, activation of players of th…

0301 basic medicinemangoPhysiologyClinical BiochemistryBiochemistry03 medical and health sciences0302 clinical medicineDownregulation and upregulationSettore BIO/10 - BiochimicaMangiferaViability assayγH2AXMolecular Biologyreactive oxygen specieschemistry.chemical_classificationreactive oxygen specieReactive oxygen speciesKinaselcsh:RM1-950apoptosisApoptosiSettore CHIM/06 - Chimica OrganicaCell BiologyMolecular biologylcsh:Therapeutics. PharmacologySettore BIO/12 - Biochimica Clinica E Biologia Molecolare Clinica030104 developmental biologychemistrycolon cancer cellApoptosisCell culture030220 oncology & carcinogenesiscolon cancer cellsSignal transductionAntioxidants
researchProduct

Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorect…

2015

ABSTRACT: Thymidylate synthase (TS) is a tumor-associated enzyme critical for DNA replication and main 5′-fluorouracil (5′-FU) target. TSPP/VAC1 is a multi-arm trial phase-Ib trial program aimed to investigate the toxicity and biomodulatory activity of a poly-epitope-peptide vaccine to TS (TSPP) in cancer patients (pts). Here, we present the results of the TSPP/VAC1/arm C trial aimed to evaluate TSPP in combination with chemo-immunotherapy in pretreated metastatic colo-rectal cancer (mCRC) pts. Twenty-nine pts, 14 males and 15 females, received poly-chemotherapy with gemcitabine [GEM; 1,000 mg/sqm, day-1], oxaliplatin [OX; 80 mg/sqm, day-2], levofolinate [100 mg/sqm, days 1–2], bolus/infusi…

0301 basic medicinemedicine.medical_specialtyepitope peptidesImmunologyGOLFIG chemo-immunotherapythymidylate synthaseGastroenterologyThymidylate synthaseCTLs03 medical and health sciences0302 clinical medicineBolus (medicine)SargramostimInternal medicinepeptide vaccineMedicineImmunology and AllergyOriginal Researchbiologybusiness.industryColon cancer; CTLs; epitope peptides; GOLFIG chemo-immunotherapy; peptide vaccine; thymidylate synthase; Immunology and Allergy; Oncology; ImmunologyGemcitabineOxaliplatinColon cancerRegimen030104 developmental biologyOncologyFluorouracil030220 oncology & carcinogenesisConcomitantImmunologyCTLbiology.proteinbusinessepitope peptidemedicine.drug
researchProduct

Impact of relative dose intensity of oxaliplatin in adjuvant therapy among stage III colon cancer patients on early recurrence: a retrospective cohor…

2020

Abstract Background Oxaliplatin-based therapy with FOLFOX-4 or CAPOX administered over 6 months remains the standard adjuvant treatment for stage III colon cancer (CC) patients. However, many patients experience dose reduction or early termination of chemotherapy due to oxaliplatin toxicity, which may increase the risk of early recurrence. The objective of this study was to analyze the relationship between the relative dose intensity of oxaliplatin (RDI-O) and early recurrence among stage III CC patients. Methods The study included 365 patients treated at five oncology centers in Poland between 2000 and 2014. Survival analysis was performed using the Kaplan-Meier method. Univariate analysis…

AdultMaleCancer Researchmedicine.medical_specialtyColorectal cancerGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineGeneticsAdjuvant therapyMedicineHumans030212 general & internal medicineRelative dose intensityRC254-282Survival analysisAgedNeoplasm StagingRetrospective StudiesAged 80 and overUnivariate analysisbusiness.industryCumulative doseProportional hazards modelNeoplasms. Tumors. Oncology. Including cancer and carcinogensRetrospective cohort studyMiddle Agedmedicine.diseaseCumulative doseOxaliplatinColon cancerAdjuvant chemotherapyOxaliplatinOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisColonic NeoplasmsFemaleNeoplasm Recurrence Localbusinessmedicine.drugResearch Article
researchProduct

Randomized Multicenter Phase II Trial of Two Different Schedules of Irinotecan Combined with Capecitabine as First-Line Treatment in Metastatic Color…

2004

BACKGROUND The aim of the current randomized Phase II study was to investigate the efficacy and safety of capecitabine combined with irinotecan as first-line treatment in metastatic colorectal carcinoma (CRC). METHODS A total of 140 patients received capecitabine at a dose of 1250 mg/m2 twice daily on Days 2–15 and irinotecan at a dose of either 300 mg/m2 on Day 1 (Arm A) or 150 mg/m2 on Days 1 and 8 (Arm B) every 3 weeks. During the course of the study, enrollment was continued using lower doses of capecitabine (1000 mg/m2 twice daily) and irinotecan (Arm A: 240 mg/m2; Arm B: 120 mg/m2) to improve the safety profile of the combinations. RESULTS Efficacy was evaluable in 134 patients (68 in…

AdultMaleCancer Researchmedicine.medical_specialtyColorectal cancerPhases of clinical researchCOLON CANCERIrinotecanGastroenterologyDeoxycytidineDrug Administration Schedulecolorectal carcinoma first-line treatment irinotecan and capecitabine combination Phase II triallaw.inventionCapecitabineRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisAdverse effectCapecitabineAgedXELIRIbusiness.industryCarcinomaCancerMiddle Agedmedicine.diseaseSurgeryIrinotecanOncologyDrug EvaluationCamptothecinFemaleFluorouracilbusinessColorectal Neoplasmsmedicine.drug
researchProduct

Proteomic Profiling of Colon Cancer Tissues: Discovery of New Candidate Biomarkers

2020

Colon cancer is an aggressive tumor form with a poor prognosis. This study reports a comparative proteomic analysis performed by using two-dimensional differential in-gel electrophoresis (2D-DIGE) between 26 pooled colon cancer surgical tissues and adjacent non-tumoral tissues, to identify potential target proteins correlated with carcinogenesis. The DAVID functional classification tool revealed that most of the differentially regulated proteins, acting both intracellularly and extracellularly, concur across multiple cancer steps. The identified protein classes include proteins involved in cell proliferation, apoptosis, metabolic pathways, oxidative stress, cell motility, Ras signal transdu…

AdultMaleProteomics0301 basic medicinetransgelinColorectal cancerpathway analysiproteomic profilingBiologymedicine.disease_causeArticleCatalysisInorganic Chemistrylcsh:Chemistry03 medical and health sciences0302 clinical medicineBiomarkers TumorTumor MicroenvironmentmedicineHumansElectrophoresis Gel Two-DimensionalProtein Interaction MapsPhysical and Theoretical ChemistryMolecular Biologylcsh:QH301-705.5SpectroscopyInnate immune systemTAGLProteomic ProfilingOrganic ChemistryCancerGeneral MedicineMiddle Agedmedicine.diseaseComputer Science Applicationspathway analysisGene Expression Regulation Neoplastic030104 developmental biologycolon cancerlcsh:Biology (General)lcsh:QD1-999030220 oncology & carcinogenesisColonic NeoplasmsNeutrophil degranulationCancer researchBiomarker (medicine)FemaleSignal transductionCarcinogenesisInternational Journal of Molecular Sciences
researchProduct

Anastomotic leakage after colon cancer resection: does the individual surgeon matter?

2016

Aim Anastomotic leakage is one of the most feared complications after colonic resection. Many risk factors for anastomotic leakage have been reported, but the impact of an individual surgeon as a risk factor has scarcely been reported. The aim of this study was to assess if the individual surgeon is an independent risk factor for anastomotic leakage in colonic cancer surgery. Method This was a retrospective analysis of prospectively collected data from patients who underwent elective resection for colon cancer with anastomosis at a specialized colorectal unit from January 1993 to December 2010. Anastomotic leaks were diagnosed according to standardized criteria. Patient and tumour character…

AdultMalemedicine.medical_specialtyBlood transfusionindividual surgeonColonColorectal cancermedicine.medical_treatmentAnastomotic Leak030230 surgeryAnastomosis03 medical and health sciences0302 clinical medicineIleorectal anastomosisRisk FactorsTask Performance and AnalysisColon cancer resectionHumansAnastomotic leakMedicineBlood TransfusionRisk factorcolon resectionColectomyAgedRetrospective StudiesAged 80 and overbusiness.industryAnastomosis SurgicalGastroenterologyPerioperativeMiddle Agedmedicine.diseaseSurgeryrisk factorcolon cancerElective Surgical ProceduresAnastomotic leakage030220 oncology & carcinogenesisColonic NeoplasmsFemaleClinical CompetencebusinessColorectal Disease
researchProduct

Accuracy of CT colonography in the preoperative staging of colon cancer: a prospective study of 217 patients

2019

Aim The purpose of the present study was to evaluate the accuracy of computed tomography colonography (CTC) in the preoperative localization and TN staging of colon cancer. CTC can be an effective technique for preoperative evaluation of colon cancer and could facilitate the selection of high-risk patients who may benefit from neoadjuvant chemotherapy. Method This was a prospective observational study conducted at a single tertiary-care centre. It involved 217 patients (225 tumours) who had colon cancer and underwent preoperative CTC and elective colectomy. The radiologist determined the TNM stage using postprocessing software with multiplanar images and virtual colonoscopy. The following c…

AdultMalemedicine.medical_specialtyVirtual colonoscopyColorectal cancermedicine.medical_treatmentColonoscopySensitivity and SpecificitySurgical planning03 medical and health sciences0302 clinical medicineCT-Colonography Colon cancer Preoperative stagingComputed Tomography ColonographyPreoperative CaremedicineHumansProspective StudiesStage (cooking)Prospective cohort studyAgedNeoplasm StagingColectomyAged 80 and overmedicine.diagnostic_testbusiness.industryPatient SelectionGastroenterologyMiddle Agedmedicine.diseasedigestive system diseasesNeoadjuvant Therapy030220 oncology & carcinogenesisColonic NeoplasmsFemale030211 gastroenterology & hepatologyRadiologybusinessColonography Computed TomographicColorectal Disease
researchProduct

Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-suppressors and effectors of TGFbeta signaling pathway in SW480 cells.

2010

International audience; Resveratrol (trans-3,4',5-trihydroxystilbene) is a natural antioxidant with cardiovascular and cancer preventive properties that is currently at the stage of pre-clinical studies for human cancer prevention. Beside its known effects on protein coding genes, one possible mechanism for resveratrol protective activities is by modulating the levels of non-coding RNAs. Here, we analyzed the effects of resveratrol on microRNA populations in human SW480 colon cancer cells. We establish that resveratrol treatment decreases the levels of several oncogenic microRNAs targeting genes encoding Dicer1, a cytoplasmic RNase III producing mature microRNAs from their immediate precurs…

Antineoplastic AgentsSmad ProteinsResveratrolBiochemistryAntioxidantsArticleTransforming Growth Factor beta1chemistry.chemical_compoundTGFβTransforming Growth Factor betaCell Line TumormicroRNAStilbenesPTENHumansRibonuclease III[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyPharmacologyOncogene ProteinsbiologyEffectorTumor Suppressor ProteinsTransforming growth factor betaMolecular biologyColon cancer; microRNAs; miR-663; Resveratrol; SW480 cells; TGFβmiR-663Cell biologyColon cancerMicroRNAsSW480 cellschemistryResveratrolbiology.proteinSignal transductionTransforming growth factorSignal Transduction
researchProduct